Brice Amadeo1,2,3, Nicolas Penel4,5, Jean-Michel Coindre6, Isabelle Ray-Coquard7,8, Karine Ligier9,10, Patricia Delafosse9,11, Anne-Marie Bouvier9,12,13, Sandrine Plouvier9,10, Justine Gallet14, Aude Lacourt14, Gaëlle Coureau14,15,9,16, Alain Monnereau14,9,17, Simone Mathoulin-Pélissier14,18, Emmanuel Desandes9,19,20. 1. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000, Bordeaux, France. brice.amadeo@u-bordeaux.fr. 2. Registre des cancers de la Gironde, Univ. Bordeaux, Inserm CIC1401, F-33000, Bordeaux, France. brice.amadeo@u-bordeaux.fr. 3. French Network of Cancer Registries, F-31000, Toulouse, France. brice.amadeo@u-bordeaux.fr. 4. Univ. Lille, F-59000, Lille, France. 5. Medical Oncology Department, Centre Oscar Lambret, F-59000, Lille, France. 6. Department of Biopathology, Institute Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France. 7. Department of Medical Oncology, Centre Leon Berard, F69000, Lyon, France. 8. University Claude Bernard Lyon 1, Lyon, France. 9. French Network of Cancer Registries, F-31000, Toulouse, France. 10. Registre Général des Cancers de Lille et de sa Région, C2RC, F59000, Lille, France. 11. Isère Cancer Registry, CHU Grenoble-Alpes, F-38000, Grenoble, France. 12. Dijon University Hospital, University of Bourgogne Franche-Comté, Besançon, France. 13. Digestive Cancer Registry of Burgundy, LNC UMR1231 EPICAD, F-21000, Dijon, France. 14. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000, Bordeaux, France. 15. Registre des cancers de la Gironde, Univ. Bordeaux, Inserm CIC1401, F-33000, Bordeaux, France. 16. Medical Information Service, Public Health Department, CHU Bordeaux, F-33000, Bordeaux, France. 17. Gironde registry of haematological malignancies, Institut Bergonié, F-33000, Bordeaux, France. 18. Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonié, Comprehensive Cancer Center, F-33000, Bordeaux, France. 19. Registre National des Tumeurs Solides de l'Enfant, CHU Nancy, F-54500, Vandœuvre-lès-Nancy, France. 20. Centre de Recherche en Epidémiologie et en Statistique, EPICEA team, Université Paris-Descartes, Inserm, UMR 1153, F-75014, Paris, France.
Abstract
BACKGROUND: The exhaustive collection of new sarcoma cases and their second histologic review offer a unique opportunity to study their incidence and time trends in France according to the major subtypes. METHODS: Data were collected from population-based cancer registries covering 22% of the French population. Crude and world age-standardized incidence rates (ASR) were estimated according to anatomic, histological and genetic groups, age and sex over the 2010-2013 period. RESULTS: Time trends in incidence were calculated by the annual percent change over the 2000-2013 period. During the most recent period (2010-2013), 3942 patients with sarcoma were included. The ASR of soft-tissue and bone sarcomas, and gastro-intestinal stromal tumors (GIST) were 2.1, 1.0 and 0.6, respectively. For the four most frequent histological subtypes (unclassified, leiomyosarcoma, GIST and liposarcoma), the ASR ranged from 0.4 to 0.7. ASRs were 1.9 for complex genomic and 1.3 for recurrent translocation sarcomas. The time-trend analysis showed a significant increase of sarcoma incidence rate between 2000 and 2005, which stabilized thereafter. Incidence rates increased for four histological subtypes (GIST, chondrosarcoma, myxofibrosarcoma, solitary fibrous tumors) and decreased for three (leiomyosarcomas, Kaposi sarcoma and fibrosarcoma). CONCLUSION: To our knowledge, this study is the first to investigate sarcoma incidence based on a systematic pathological review of these cancers and on the updated sarcoma classifications. Due to the paucity of literature on sarcomas, future studies using data from population-based cancer registries should consider a standardized inclusion criterion presented in our study to better describe and compare data between countries.
BACKGROUND: The exhaustive collection of new sarcoma cases and their second histologic review offer a unique opportunity to study their incidence and time trends in France according to the major subtypes. METHODS: Data were collected from population-based cancer registries covering 22% of the French population. Crude and world age-standardized incidence rates (ASR) were estimated according to anatomic, histological and genetic groups, age and sex over the 2010-2013 period. RESULTS: Time trends in incidence were calculated by the annual percent change over the 2000-2013 period. During the most recent period (2010-2013), 3942 patients with sarcoma were included. The ASR of soft-tissue and bone sarcomas, and gastro-intestinal stromal tumors (GIST) were 2.1, 1.0 and 0.6, respectively. For the four most frequent histological subtypes (unclassified, leiomyosarcoma, GIST and liposarcoma), the ASR ranged from 0.4 to 0.7. ASRs were 1.9 for complex genomic and 1.3 for recurrent translocation sarcomas. The time-trend analysis showed a significant increase of sarcoma incidence rate between 2000 and 2005, which stabilized thereafter. Incidence rates increased for four histological subtypes (GIST, chondrosarcoma, myxofibrosarcoma, solitary fibrous tumors) and decreased for three (leiomyosarcomas, Kaposi sarcoma and fibrosarcoma). CONCLUSION: To our knowledge, this study is the first to investigate sarcoma incidence based on a systematic pathological review of these cancers and on the updated sarcoma classifications. Due to the paucity of literature on sarcomas, future studies using data from population-based cancer registries should consider a standardized inclusion criterion presented in our study to better describe and compare data between countries.
Entities:
Keywords:
Cancer registry; France; Incidence; Sarcoma; Trends in incidence
Authors: S Verbeke; R Perret; V Chaire; E Richard; V Velasco; F Giles; L Cavalcante; A Italiano Journal: J Hematol Oncol Date: 2021-12-02 Impact factor: 17.388